A Population‐Based Study of Infection‐Related Hospital Mortality in Patients With Dermatomyositis/Polymyositis
Open Access
- 20 October 2014
- journal article
- dermatomyositis
- Published by Wiley in Arthritis Care & Research
- Vol. 67 (5) , 673-680
Abstract
Objective: Dermatomyositis (DM) and polymyositis (PM) are debilitating inflammatory myopathies associated with significant mortality. We evaluated the relative contribution of infection to hospital mortality in a large population‐based study of individuals with PM/DM.Methods: Data derive from the 2007 to 2011 Healthcare Cost and Utilization Project National Inpatient Samples and include all hospital discharges that met a validated administrative definition of PM/DM. The primary outcome was hospital mortality. Variables for infections and comorbidities were generated from discharge diagnoses using validated administrative definitions. Logistic regression was used to investigate the relationship between infection and mortality in individuals with PM/DM, adjusting for sociodemographics, utilization variables, and comorbidities. Relative risks (RRs) were calculated to compare the overall prevalence of specific infections and associated mortality in PM/DM hospitalizations with those seen in the general hospitalized population.Results: A total of 15,407 hospitalizations with PM/DM met inclusion criteria for this study and inpatient mortality was 4.5% (700 deaths). In adjusted logistic regression analyses, infection (odds ratio [OR] 3.4, 95% confidence interval [95% CI] 2.9–4.0) was the strongest predictor of hospital mortality among individuals with PM/DM. Bacterial infection (OR 3.5, 95% CI 3.0–4.1), comprised primarily of pneumonia and bacteremia, and opportunistic fungal infections (OR 2.5, 95% CI 1.5–4.0) were independently associated with hospital mortality. The overall burden of infection in hospitalizations with PM/DM was significantly increased in comparison with the general hospitalized population (RR 1.5, 95% CI 1.4–1.6).Conclusion: Among hospitalized individuals with PM/DM, infection is the leading cause of mortality. Strategies to mitigate infection risk in both the clinic and hospital settings should be evaluated to improve disease outcomes.Keywords
Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23-AR-0259, P60-AR-3308)
- Rosalind Russell Medical Research Center for Arthritis at the University of California, San Francisco
- NIH (3UL1-RR-4131-04S1)
This publication has 28 references indexed in Scilit:
- Is the presence of medical trainees associated with increased mortality with weekend admission?BMC Medical Education, 2014
- Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample surveyArthritis Research & Therapy, 2013
- Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysisBMC Musculoskeletal Disorders, 2012
- Accuracy of pharmacy and coded‐diagnosis information in identifying tuberculosis in patients with rheumatoid arthritisPharmacoepidemiology and Drug Safety, 2012
- Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprineArthritis Research & Therapy, 2012
- The Accuracy of Administrative Data Diagnoses of Systemic Autoimmune Rheumatic DiseasesThe Journal of Rheumatology, 2011
- Herpes Zoster Risk Factors in a National Cohort of Veterans with Rheumatoid ArthritisClinical Infectious Diseases, 2009
- Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patientsJournal of Clinical Epidemiology, 2009
- Computerized definitions showed high positive predictive values for identifying hospitalizations for congestive heart failure and selected infections in Medicaid enrollees with rheumatoid arthritisPharmacoepidemiology and Drug Safety, 2008
- Prognosis and mortality of polymyositis and dermatomyositis patientsClinical Rheumatology, 2006